On June 12, 2025 Scenic Biotech reported the extension of its research collaboration with Bristol Myers Squibb (Press release, Scenic Biotech, JUN 12, 2025, View Source [SID1234653832]). The growth of this partnership highlights the unique power of our Cell-Seq platform, which unlocks the underlying genetic interactions of cellular pathways for novel drug targets.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Together, we are working to identify target biology for indication selection, and expansion, driving progress towards novel treatments for severe diseases. It’s a testament to the productive collaboration and shared vision between our teams.

In parallel to advancing our proprietary pipeline in neuro- and metabolic diseases, we remain committed to supporting our partners in shaping the future of medicine and improving patient outcomes. We look forward to the continued progress we’ll make together!